Explore our Deck
Find the company overview and discover with us exciting scientific developments and business opportunities.
Latest News
Our Research
IGC-AD1
Is designed to target neuroinflammation, potentially stabilize CB1r function and address neurotransmitter imbalances, all hallmarks associated with agitation in Alzheimer Dementia
TGR-63
A small molecule designed to break down plaque formation in the brain, exhibiting outstanding biocompatibility, the ability to breach the blood–brain barrier, and pre-clinical behavioral efficacy.
A.I.
To mine the depths of decades-worth of Alzheimer’s research, bringing to light novel insights and pioneering advanced treatments faster than ever for a healthier elderliness.
CALMA
Welcome to CALMA, a multicenter Phase 2 clinical trial designed to evaluate the safety and efficacy of IGC-AD1 for treating agitation associated with Alzheimer’s dementia.
Locations
Our company has operations in different countries
manufacturing vertical and R&D capabilities.
